uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
March 03 2017 - 7:00AM
-- Lexington, MA-based Gene Therapy Facility
Recognized for Enabling Manufacturing Excellence --
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today
announced that it has been recognized by Frost & Sullivan as a
2017 Manufacturing Leadership Awards winner for outstanding
achievement in Engineering & Production Technology Leadership
related to its Lexington, Massachusetts gene therapy manufacturing
facility.
uniQure’s Lexington-based facility is one of the
largest, most versatile gene therapy manufacturing facilities in
the world. Over the past four years, uniQure has invested
more than $25 million in designing, constructing and equipping its
55,000 square foot facility with state-of-the-art laboratories and
commercial-scale production capabilities. The facility offers
500-liter capacity with the ability to expand to up to 2,000 liters
when needed.
“The innovative design of our facility, which
incorporated 3D modeling and single-use components, required
substantially less upfront capital expenditures and enables us to
operate at significantly lower costs compared to other production
systems,” stated Lance Weed, vice president of operations for
uniQure. “Our use of disposable components in our manufacturing
process reduces the need for maintenance and testing, lowers the
risk of contamination, enables rapid product changeovers, and
requires substantially less personnel to operate.”
“uniQure is committed to manufacturing
excellence in gene therapy and we are delighted that Frost &
Sullivan has recognized our achievements in this regard,” stated
Matt Kapusta, chief executive officer of uniQure. “We
continue to believe that our leading manufacturing capabilities
provide us a significant competitive advantage in rapidly
delivering gene therapies to patients, including our lead product
candidate in hemophilia B, for which we plan to begin a global
pivotal study in 2018.”
uniQure will be recognized at the 13th Annual
Manufacturing Leadership Awards Gala, which is to be held on the
last day of the Manufacturing Leadership Summit, June 12-14, 2017
at the Hyatt Regency Huntington Beach Resort and Spa in Huntington
Beach, CA.
Additional Resources
- 2017 Manufacturing Leadership Award Winners
- About the 13th Annual Manufacturing Leadership Summit
- About the Manufacturing and Leadership Council
- About Frost and Sullivan
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and cardiovascular diseases.
www.uniQure.com
About the Frost & Sullivan
Manufacturing Leadership AwardsThe Frost & Sullivan
Manufacturing Leadership Awards, now in their 13th year, honor
manufacturing companies and individual manufacturing leaders that
are shaping the future of global manufacturing. Winning projects
and individual manufacturing leaders have demonstrated achievement
in one of a wide range of categories, and are chosen by a panel of
expert judges for results that have delivered clear and compelling
value, return on investment, and other tangible outcomes. There
will be several winners in each category, including one High
Achiever’s Award in each category, as well as a 2017 Manufacturer
of the Year for both small and large enterprises. Also unveiled at
the Gala will be the ML Awards Manufacturing Leader of the Year and
Lifetime Achievement Award winners.
The theme for the 13th Annual Manufacturing
Leadership Summit is “Manufacturing 4.0 in Action.” The event
enables senior-level executives in all aspects of manufacturing an
opportunity to network with and learn from the best minds in the
industry
For more information on the Manufacturing
Leadership Awards or the Manufacturing Leadership Summit, please go
to www.mlsummit.com.
uniQure Forward-Looking
StatementsThis press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements include, but are not limited to, statements regarding
the implementation and effects of the Company’s new strategic and
organizational changes, the development of our gene therapy product
candidates, the success of our collaborations and the risk of
cessation, delay or lack of success of any of our ongoing or
planned clinical studies and/or development of our product
candidates. Our actual results could differ materially from those
anticipated in these forward-looking statements for many reasons,
including, without limitation, risks associated with corporate
reorganizations and strategic shifts, collaboration arrangements,
our and our collaborators’ clinical development activities,
regulatory oversight, product commercialization and intellectual
property claims, as well as the risks, uncertainties and other
factors described under the heading "Risk Factors" in uniQure’s
2015 Annual Report on Form 20-F filed with the Securities and
Exchange Commission on April 4, 2016. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
uniQure Contacts:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024